You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis
|
|---|---|
| Published in |
BMC Infectious Diseases, June 2017
|
| DOI | 10.1186/s12879-017-2495-5 |
| Pubmed ID | |
| Authors |
Khalid Eljaaly, Samah Alshehri, Ahmed Aljabri, Ivo Abraham, Mayar Al Mohajer, Andre C. Kalil, David E. Nix |
| Abstract |
Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however, the need for empiric atypical coverage remains controversial. Our objective was to evaluate the impact of antibiotic regimens with atypical coverage (a fluoroquinolone or combination of a macrolide/doxycycline with a β-lactam) to a regimen without atypical antibiotic coverage (β-lactam monotherapy) on rates of clinical failure (primary endpoint), mortality, bacteriologic failure, and adverse events, (secondary endpoints). We searched the PubMed, EMBASE and Cochrane Library databases for relevant RCTs of hospitalized CAP adults. We estimated risk ratios (RRs) with 95% confidence intervals (CIs) using a fixed-effect model, but used a random-effects model if significant heterogeneity (I (2) ) was observed. Five RCTs with a total of 2011 patients were retained. A statistically significant lower clinical failure rate was observed with empiric atypical coverage (RR, 0.851 [95% CI, 0.732-0.99; P = 0.037]; I (2) = 0%). The secondary outcomes did not differ between the two study groups: mortality (RR = 0.549 [95% CI, 0.259-1.165, P = 0.118], I (2) = 61.434%) bacteriologic failure (RR = 0.816 [95% CI, 0.523-1.272, P = 0.369], I (2) = 0%), diarrhea (RR = 0.746 [95% CI, 0.311-1.790, P = 0.512], I (2) = 65.048%), and adverse events requiring antibiotic discontinuation (RR = 0.83 [95% CI, 0.542-1.270, P = 0.39], I (2) = 0%). Empiric atypical coverage was associated with a significant reduction in clinical failure in hospitalized adults with CAP. Reduction in mortality, bacterial failure, diarrhea, and discontinuation due to adverse effects were not significantly different between groups, but all estimates favored atypical coverage. Our findings provide support for the current guidelines recommendations to include empiric atypical coverage. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 19% |
| Saudi Arabia | 5 | 16% |
| Spain | 2 | 6% |
| Venezuela, Bolivarian Republic of | 1 | 3% |
| United Kingdom | 1 | 3% |
| Oman | 1 | 3% |
| Estonia | 1 | 3% |
| Unknown | 14 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 74% |
| Scientists | 5 | 16% |
| Practitioners (doctors, other healthcare professionals) | 3 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 91 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 15% |
| Other | 7 | 8% |
| Student > Master | 7 | 8% |
| Student > Doctoral Student | 7 | 8% |
| Student > Bachelor | 7 | 8% |
| Other | 20 | 22% |
| Unknown | 29 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Immunology and Microbiology | 3 | 3% |
| Agricultural and Biological Sciences | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 35 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2022.
All research outputs
#1,684,494
of 25,728,855 outputs
Outputs from BMC Infectious Diseases
#421
of 8,693 outputs
Outputs of similar age
#31,968
of 332,634 outputs
Outputs of similar age from BMC Infectious Diseases
#13
of 181 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,693 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,634 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 181 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.